MedTrace Logo

Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

NCT07402213 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-02-11

No results posted yet for this study

Summary

This Phase III Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

Conditions

Interventions

DRUG

JYB1904

300 mg JYB1904 injection administered SC every 12 weeks (Q12W) from Day 1 to Week 48.

DRUG

Placebo+JYB1904

Placebo administered SC on D1 and W12; 300 mg JYB1904 injection administered SC every 12 weeks (Q12W) from W24 to W48.

Sponsors & Collaborators

  • Jemincare

    lead INDUSTRY

Principal Investigators

  • Jianzhong Zhang · Peking University People's Hospital

  • Cheng Zhou · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2027-06-30
Completion
2028-04-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07402213 on ClinicalTrials.gov